Tesamorelin before and after: Frequently asked questions

Yes, and rapidly. Discontinuation studies show approximately 60–80% VAT regain within 12–16 weeks of stopping tesamorelin. The peptide does not reprogram adipocyte biology. It shifts lipolysis while it's active, but once dosing ceases, visceral adipocytes refill through normal lipogenesis pathways. To maintain VAT reductions long-term, either continue tesamorelin at maintenance dosing (some clinicians use 2mg 5 days per week rather than daily), transition to a structured caloric deficit with resistance training, or combine periodic tesamorelin cycles (12 weeks on, 8 weeks off) with aggressive dietary control during off periods.

Elevated IGF-1 confirms that tesamorelin is stimulating GH secretion, but VAT reduction depends on whether free fatty acids released from visceral adipocytes are being oxidized rather than re-esterified. If caloric intake matches or exceeds expenditure, lipolysis may be occurring without net fat loss. Reduce daily intake by 200–300 calories below calculated maintenance and ensure you're performing moderate-intensity activity at least 4–5 days per week. Hepatic lipid oxidation capacity is enhanced by aerobic exercise and fasted morning activity, both of which shift substrate utilization toward fatty acid oxidation.

Joint pain and carpal tunnel syndrome are GH-related side effects caused by fluid retention and soft tissue swelling. These symptoms occur in approximately 10–15% of patients and are dose-dependent. Reduce your tesamorelin dose to 1mg daily for 2 weeks. Symptoms typically resolve within 7–10 days. Once symptoms clear, resume 2mg daily. If symptoms recur, remain at 1mg or alternate between 2mg and 1mg on a 5-day/2-day cycle. The VAT reduction at 1mg is suboptimal but still measurable, and some patients tolerate alternating dosing better than continuous 2mg.

Continue dosing through at least week 20 before concluding the peptide is ineffective. Clinical trial data shows the steepest VAT reductions occur between weeks 16 and 24, and waist circumference lags behind CT-measured VAT loss by 4–6 weeks. If you're measuring with a tape measure rather than imaging, you may be missing subclinical changes that haven't yet crossed the perceptual threshold. CT or MRI at baseline and week 20 provides objective confirmation. If VAT has decreased by 10% or more, the peptide is working even if you don't perceive visual change yet.

Rotate injection sites and monitor for resolution within 48–72 hours. Mild erythema or transient edema at injection sites occurs in approximately 15–20% of subjects and typically resolves without intervention as injection technique improves. Persistent swelling lasting more than three days, or swelling in non-injection areas (hands, ankles), may indicate fluid retention from elevated GH levels. Contact your supervising physician to assess whether dose reduction is warranted. Real Peptides protocols emphasize site rotation (alternating between abdomen quadrants) to minimize localized tissue irritation.

Discard it. Tesamorelin peptide structure degrades irreversibly at temperatures above 8°C. A vial left at room temperature (20–25°C) for 8+ hours loses enough potency that continuing the protocol wastes both time and money. There's no salvage method: heating, re-cooling, or visual inspection won't restore peptide integrity. Replace the vial and ensure your storage setup includes a dedicated medication refrigerator or cold pack system for travel.

Continue the protocol and request imaging if available. Visceral fat mobilization precedes visual changes by 6–10 weeks in most subjects. CT scans at week 8 often show 8–12% reductions that won't be externally visible until week 14–16. Early discontinuation is the most common mistake: the compound works on a cumulative timeline, not a linear one. If fasting glucose or triglycerides are improving, the mechanism is active even if the mirror hasn't changed yet.